Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia

INTRODUCTION: Flumatinib is a novel, oral breakpoint cluster region-abelson (BCR-ABL) tyrosine kinase inhibitor that has demonstrated manageable safety and promising efficacy in patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML). METHODS: This study evaluated the pharmac...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Bo, Qi, Junyuan, Sun, Mingyuan, Zheng, Weiwei, Wei, Yongyue, Wang, Jianxiang, Zhang, Fengkui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939828/
https://www.ncbi.nlm.nih.gov/pubmed/36814813
http://dx.doi.org/10.3389/fonc.2023.1101738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939828/
https://www.ncbi.nlm.nih.gov/pubmed/36814813
http://dx.doi.org/10.3389/fonc.2023.1101738

Ejemplares similares